Virtu Financial LLC Purchases New Position in Exagen Inc. (NASDAQ:XGN)

Virtu Financial LLC acquired a new stake in Exagen Inc. (NASDAQ:XGN) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 11,203 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.06% of Exagen at the end of the most recent quarter.

Separately, Palumbo Wealth Management LLC boosted its position in shares of Exagen by 13.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after acquiring an additional 10,340 shares during the period. 75.25% of the stock is owned by institutional investors and hedge funds.

Exagen Stock Performance

Exagen stock opened at $3.93 on Wednesday. Exagen Inc. has a 1-year low of $1.30 and a 1-year high of $6.22. The firm has a market cap of $70.34 million, a P/E ratio of -4.18 and a beta of 1.40. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54. The firm has a 50-day moving average of $3.89 and a 200-day moving average of $3.65.

Wall Street Analyst Weigh In

XGN has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price target on shares of Exagen in a research report on Monday, January 13th. Canaccord Genuity Group lifted their target price on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, William Blair reissued an “outperform” rating on shares of Exagen in a research note on Wednesday, March 12th.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).